Skip to main content

ERRATUM article

Front. Pharmacol., 26 February 2019
Sec. Pharmacology of Anti-Cancer Drugs
Volume 10 - 2019 | https://doi.org/10.3389/fphar.2019.00213

Erratum: Anti-metastatic Properties of Naproxen-HBTA in a Murine Model of Cutaneous Melanoma

This article is an erratum on:

  1. Anti-metastatic Properties of Naproxen-HBTA in a Murine Model of Cutaneous Melanoma

    1. Read original article
\r\nFrontiers Pharmacology Editorial Office*Frontiers Pharmacology Editorial Office*
  • Pharmacology Editorial Office, Frontiers Media SA, Lausanne, Switzerland

An Erratum on
Anti-metastatic Properties of Naproxen-HBTA in a Murine Model of Cutaneous Melanoma

Ercolano, G., De Cicco, P., Frecentese, F., Saccone, I., Corvino, A., Giordano, F., et al. (2019). Front. Pharmacol. 10:66. doi: 10.3389/fphar.2019.00066

The statement declaring the relationship between the handling editor and two of the authors has been clarified for transparency of the process. The updated statement should read, in full:

After the conclusion of the peer review, the handling editor noticed and declared a collaboration and shared affiliation with two of the authors, VaC and ViC. These authors provided an additional analysis requested by a reviewer during review. They were later added as co-authors and identified to the editor after the provisional acceptance of the manuscript. Under these exceptional circumstances, the relationship did not affect the objectivity of the review process, and this situation is being declared for transparency.

The publisher apologizes for this oversight. The original article has been updated.

Keywords: cyclooxygenases (COXs), hydrogen sulfide (H2S), non-steroidal anti-inflammatory drugs (NSAIDs), melanoma, target-therapy, apoptosis

Citation: Frontiers Pharmacology Editorial Office (2019) Erratum: Anti-metastatic Properties of Naproxen-HBTA in a Murine Model of Cutaneous Melanoma. Front. Pharmacol. 10:213. doi: 10.3389/fphar.2019.00213

Received: 20 February 2019; Accepted: 20 February 2019;
Published: 26 February 2019.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2019 Frontiers Pharmacology Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Pharmacology Editorial Office, pharmacology.editorial.office@frontiersin.org

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.